Introduction. Although hepatitis E virus (HEV) is mainly transmitted via the faecal-oral route, the rate of HEV transmission via blood donation is on the rise. However, the seroprevalence of HEV among blood donors is not well established and is thought to be affected by the type of diagnostic assay used. We aimed to evaluate performance and correlation among widely used commercial diagnostic assays for the seroprevalence assessment of HEV-IgM/IgG among blood donors.
INTRODUCTION
HEV infection is among the most common causes of acute viral hepatitis worldwide. HEV is a small, non-enveloped, single-stranded, positive-sense RNA virus and known as enterically transmitted non-A, non-B hepatitis [1] . HEV belongs to the family Hepeviridae and genus Orthohepevirus. This genus is divided into four species containing multiple genotypes, where all the HEVs infecting humans belong to the species Orthohepevirus A. To date, four HEV genotypes from this species have been identified as infecting humans, and these are classified based on whole-genome analysis. Interestingly, all these four belong to one serotype according to neutralization assay [2] [3] [4] . In most cases, HEV infection is self-limiting and asymptomatic. However, in other cases, infection results in typical symptoms of acute hepatitis such as jaundice, hepatosplenomegaly and elevated liver transaminases [5] . According to the World Health Organization (WHO), 20 million new HEV cases are recorded annually. HEV-specific mortality is about 3.3 % worldwide, accounting for almost 44 000 deaths per year [1] . In addition, 10-30 % of pregnant women and more than 75 % of HEV-infected patients with underlying liver conditions die due to HEV infection [6] [7] [8] .
HEV is mainly transmitted via the faecal-oral route, as well as by zoonotic transmission from infected animals including camel, deer, the domestic pig and wild boar [1] .
Interestingly, occasional transmission of HEV infection via blood transfusion has been documented as increasing in several countries around the world [9] [10] [11] [12] [13] [14] [15] . Therefore, blood transfusion is considered a potential risk for HEV spread, which poses a considerable threat to patients requiring blood transfusion [16] . Accordingly, HEV could represent a life-threatening infection in immune-compromised blood or organ recipients, and therefore there is a paucity of evidence for classifying HEV as an emergent blood pathogen regarding global blood supplies. Although detection of HEV antibodies is useful in the diagnosis of current or past HEV infection, studies have shown that these tests do not provide sufficient confirmatory evidence as to whether donor blood products are infectious and contain HEV-RNA [17, 18] .
Although serological assays are more feasible in terms of cost and simplicity, their diagnostic sensitivity and specificity in detecting HEV are relatively low [19] . Accordingly, HEV-RNA detection remains the gold standard to determine viraemia [20, 21] . Clinically, RNA and antibody detection in the blood reflect different stages of a disease. HEV-RNA testing cannot be considered as a gold standard test to confirm assays that rely on antibody detection, such as IgG and IgM, because viraemia does not always coincide with the antibody response in the natural course of HEV infection. Recent studies suggest that conducting more scientific investigations, such as seroprevalence studies, is crucial to verifying whether additional methods for HEV-RNA detection in blood banks are necessary [18] . Moreover, using an expensive test such as HEV-RNA PCR on a large population of blood donors, or during outbreaks, as a routine screening tool is economically inefficient. Therefore, in this study there was a pressing need to establish a silver standard as an equivalence reference or confirmatory assay to evaluate the performance of antibody assays [22] . In this approach, the sample is considered positive only if testing positive by three or more different immunoassays.
There is currently no FDA-approved serological assay for HEV clinical diagnosis. The available commercial assays can only aid in screening for HEV and can be used in epidemiological studies, yet none is known to be confirmatory [4] . More critically, previous studies have observed that seroprevalence among healthy or acute hepatitis individuals is markedly affected by the type of laboratory assay [4, 16] . This led to a huge variation in seroprevalence in the same population. For instance, it was noted in three different studies conducted on the same study population over the same period in Germany that the seroprevalence of HEV IgG ranged between 6 and 16 % [23] [24] [25] . Likewise, studies in which commercial assays were used for detection of HEV IgM, among acute hepatitis samples, resulted in wide variation in diagnostic performance [26] [27] [28] . Accordingly, HEV seroprevalence is affected not only by the study population, geographic distribution and the time period (season), but also by the type of detection assay used. Therefore, this study aimed to assess the concordance between widely used commercial assays that rely on the detection of IgM/IgG to assess HEV seroprevalence among large populations of blood donors from different nationalities and backgrounds, and to evaluate their performance as a screening tool in the absence of the costly gold standard PCR.
METHODS
Ethical compliance and sample collection Ethical clearance was obtained from the Hamad Medical Corporation (HMC) and Qatar University (QU) Institutional Review Boards (HMC-IRB #14292/14 and QU-IRB #556-EA/16, respectively) prior to the study sample collection. A total of 1049 blood samples of apparently healthy blood donors was obtained from the blood donation centre of the HMC during the period June 2013-June 2016. The blood samples were originally collected for other studies [16, [29] [30] [31] [32] . The sampling, transport and storage methods and details of the study population were described previously [16, 29, [31] [32] [33] .
Assays used for detection of HEV antibodies
Enzyme-linked immunosorbent assay (ELISA) Commercial ELISA kits from four different companies were used for qualitative detection of HEV IgG and IgM antibodies in the sera of blood donors:
(1) MP Dignostics (HEV-IgG) ELISA catalogue no.
0721150096T Relative performance (titre quantification) Relative performance (titre quantification) was performed to determine the least amount of anti-HEV concentration (titre detection limit) detectably by each assay. Five samples testing positive for HEV-IgG by all serological assays (Table 5) were chosen randomly regardless of their IgM test results. Tests were performed on 10-fold serially diluted (1 : 10, 1 : 100, 1 : 1000 and 1 : 10 000) samples [28, 34] . A 1 : 5000 dilution was performed on samples that were negative at 1 : 10 000 dilution. Finally, a score of 1 to 5 was given to any positive result based on the sensitivity in detecting the lowest anti-HEV concentration (titrate). Thus, a score of 5 represents an anti-HEV concentration that was detected at the highest dilution (lowest titrate).
Diagnostic performance evaluation
IgG antibodies were tested since HEV-IgG persists for a long period following exposure/clearance of HEV infection. Due to the absence of approved HEV-IgG confirmatory tests, we developed a 'silver standard' evaluation to be used for diagnosis of HEV, after referring to senior expert opinion in the field. The main idea behind the silver standard was to increase the probability of true positives (TPs) and true negatives (TNs), and to decrease the probability of false positives (FPs) and false negatives (FNs). In the proposed silver standard test, only samples that tested positive by three or more different sets of assay were considered positive. Diagnostic performance evaluation for the HEV IgG assays was then determined with respect to the silver standard that we had developed. Diagnostic sensitivity, specificity and efficiency were calculated for each assay against the silver standard as follows: sensitivity = [true positive/(true positive + false negative)*100]; specificity = [true negative/ (true negative + false positive)*100]; efficiency = [(true positive + true negative)/(true positive + true negative + false positive + false negative)] for each serological assay used to detect HEV IgM.
Statistical analysis
Cohen's kappa value was calculated to determine the level of agreement of the assays used for blood donors. In addition, ROC curve analysis was used to obtain the area under the curve (AUC) for the assays to determine the ideal cutoff value that would enhance diagnostic accuracy. AUC expresses the accuracy of the test in discriminating positive (diseased) and negative values (none diseased). Statistical Package for the Social Sciences (SPSS) software version 23.0 was used to analyse the quantitative data. 
RESULTS
A total of 1049 samples from blood donors of different nationalities (n=83) was included in this study. The demographic characteristics of the blood donors are summarized in Table 2 . The seroprevalence and current disease rate varied by age and nationality. This was supported by another study where HEV seroprevalence increased with age and was more prevalent in Sudanese and Pakistani patients [16] . Initially, seroprevalence was determined for both IgG and IgM antibodies using three different ELISA assays (Wantai, MP and Euroimmun) and one immunoblot-based assay (Mikrogen). Subsequently, the diagnostic sensitivity, specificity and efficiency of each kit were calculated against the silver standard to determine the performance characteristics of HEV-IgG assays. As shown in Table 4 , all assays showed sensitivity values above 98 %, except for Euroimmun, which had a sensitivity value of 61.5 %. However, the four assays showed high specificity values, above 96 % ( Relative performance (Titre quantitation) of different HEV-IgG diagnostic assays using anonymous positive donor samples Relative performance was calculated for each assay in order to compare the HEV-IgG detection limits of all assays. The relative performance, from five randomly selected HEVIgG-positive samples, was determined ( Table 6 ). The samples were selected based on testing positive by all four HEV-IgG assays. The highest detection limit (titre) for HEV-IgG was identified by Mikrogen, at a dilution of 1 : 10 000 (titre score of 19), followed by Euroimmun at a dilution of 1 : 1000 (titre score of 11).
DISCUSSION
We analysed HEV seroprevalence using different immunoassays to develop a better evaluation tool for the diagnosis and estimation of the seroprevalence of HEV infection. Moreover, this study includes data on subjects of different nationalities, as the actual Qatari population accounts for less than 20% of the study population (Table 2) . A major element of this study is the inclusion of a large sample size of blood donors representing countries from around the globe, to evaluate the seroprevalence of anti-HEV IgM and IgG using a range of immunological binding assays. The seroprevalence of HEV ranged 0.2-2.6% and 10.3-18.1 % for IgM and IgG, respectively. This marked discrepancy between assays has a substantial impact on estimation of the actual seroprevalence of HEV in any population.
As none of the assays used is considered a confirmatory test per se, we propose a silver standardization protocol, incorporating consultation with experts in virology, that is based on the results of multiple tests. This approach provides a better assessment among assays when a confirmatory test is lacking. A silver standard was used to evaluate the performance of different serological assays. It gives a baseline and guidance for other laboratories to select the highestperforming assay. However, PCR is usually used to measure the level of viraemia but HEV RNA in samples does not always correspond to antibody levels. Moreover, the high cost of running PCR as a screening tool on a large population of blood donors puts a huge financial burden on health system resources. Consequently, a performance The Asian group includes subjects from Sirlanka, Bangladesh, Nepal, Philippines and Pakistan. The Western group includes subjects from the USA, the UK, Brazil, France, Germany, Ireland, Italy, the Netherlands, Spain, Romania, New Zealand and Australia. Others: the majority from MENA not included above.
characteristic for each assay was calculated with respect to the silver standard. As illustrated in Table 4 , MP IgG-ELISA showed the highest sensitivity, specificity, overall agreement with the silver standard and kappa value, followed by Wantai ELISA. A seroprevalence score of 16.1 % was yielded by MP-IgG ELISA, which is the closest score yielded by the silver standard (14.9 %) ( Table 3) ; interestingly the MP IgG kit is the only one in which the wells are coated with three different recombinant proteins (Table 1) . Overall, all the other kits have high sensitivity, specificity and a narrow confidence interval when compared to the silver standard. However, Euroimmun ELISA possessed the lowest sensitivity, which may be due to its cut-off determination criteria or even the antigen concentration of the coated wells. This could be due to the starting dilution, which was 1 : 100. The finding may rule out the concentration issue, but rather, questions the efficiency of coated peptides in detecting different antibody responses by diverse HEV genotypes.
Additionally, Euroimmun showed poor agreement with the silver standard.
The seroprevalnce of HEV IgM was examined using four different serological assays. A total of 52 samples were HEV IgM-positive out of 1049 samples (Table 7) . Similarly, a previous seroprevalence study examining 5854 blood donor samples revealed that only 32 tested positive for HEV IgM. However, only four samples were confirmed by RT-PCR [16] . This suggests that detection of HEV IgM in blood donors with acute infection may not be accurate since RNA and IgM antibody titres vary between different HEV infection stages. In addition, the donor status could be either (i) virus free/antibody free, (ii) virus free/antibody positive (recovered and cleared infection), (iii) virus positive/antibody negative (acute infection, too early for antibody production or detection) or (iv) virus positive/antibody positive (recovering). Therefore, these assays cannot accurately determine iwhether active infection is present, nor can they accurately detect acute n: number of samples. *Silver standard: confirmatory test in which samples positive (n=156) or negative (n=889) by at least three assays were considered true positive (TP) or true negative (TN), respectively. Silver standard was not performed for IgM, since the number of positive samples was very low and thus the silver standard could not be established. a, MP Total: measures HEV IgG, IgM and IgA.
b, Wantai Ag: detects HEV antigen. infection prior to antibody production; or the threshold levels of the assays used may be exceeded. The use of the imperfect gold standard 'silver standard' could lead to what is called 'imperfect gold standard bias'. The effect of this bias depends on whether the errors on the 'silver standard' are correlated with errors on the index test, which might expose the results to misclassifications leading to falsely decreased sensitivity and specificity [35] .
The above-mentioned results are not in line with the relative performance analysis, since Mikrogen and Euroimmun were able to detect IgG in samples diluted up to 1 : 10 000 and 1 : 1000, respectively. On the other hand, the MP and Wantai assays were only able to detect IgG in samples diluted up to 1 : 10 and 1 : 100, respectively. This is dependent on many factors, including: the antigen type and the amount coated on the plate; the nature of secondary antibodyies; whether a monoclonal or polyclonal antibody was used; nd the incubation period. Although there is only one serotype, commercial assays are designed to detect different recombinant epitopes (ORF1, ORF2, ORF3) or combinations thereof that are derived from different genotypes (genotypes 1 to 3). Although genotype 3 is the most prevalent genotype worldwide, no data areon the most prevalent genotype in the Gulf region. This could lead to discrepancies between assays and lack of sensitivity, particularly in our study where we used samples from different nationalities, mainly from Asia and the MENA region. As noted in Table 1 , both Mikrogen and Euroimmun recommend diluting the sample 100-fold. Although Wantai and MP ELISAs use 10-and 20-fold dilution, respectively, their detection limits were lower than Mikrogen and Euroimmun. Even though the assays that recommend using a lower sample to diluent ratio require a longer incubation period, this did not improve the sensitivity issue. All assays recommend incubation with the conjugate for 30 min. In addition, MP ELISA showed the highest sensitivity and specificity among other immunoassays. This could be due to the fact that this assay utilizes antigens encoded by ORF3. These antigens represent the surface (glycoproteins) of the virus, which are the primary target of the antibody response, and this partly suggests the adequacy of using these in binding assays [36] . In contrast, other kits utilize the ORF2 antigen, which is the virus capsid protein.
In conclusion, the available serological assays of HEV antibodies show discrepancies in their results. Therefore, the precise seroprevalence of HEV antibodies remains to be determined. In addition, these assays cannot be used individually to provide an accurate diagnosis of HEV infection, due to the wide variation in their sensitivities and specificities. Despite the fact that RT-PCR is considered the gold standard for the diagnosis of acute HEV infections and for determining the level of viraemia in blood donors, it has several limitations including high cost and the requirement of expertise, especially in the context of developing countries where resources are scarce. Owing to funding limitations, it was not practical in this study to perform RT-PCR for the 1049 samples. It should be clarified that serology assays detect anti-HEV antibodies using various antigens at different stages of active or prior HEV infection. However, HEV infection could be passed on during blood product transfusion when antibody levels are 'negative' but the pathogen is present -i.e. viraemia. Therefore, we recommend selective screening of blood donors for HEV RNA, especially for high-risk recipients such as immunocompromised and pregnant women, to prevent virus-positive donors from providing products for blood transfusion. Furthermore, standardization of the diagnostic procedures and the availability of efficiency panels are required to achieve accurate assessment of HEV seroprevalence and diagnosis. Note: 1: <1:10, 2: 1:100, 3: 1:1,000, 4: 1:5,000, 5: 1: 10,000. 
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